New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
16:27 EDTITMN, LOCK, CPB, BRCM, TXN, MU, NVDA, AZN, PFE, DTV, TOn The Fly: Closing Wrap
Stocks on Wall Street were higher following a trading day marked by light volume, a quiet economic calendar and two headline making M&A announcements. The averages began the day slightly below the flat line, but within minutes the Nasdaq and S&P 500 made it into positive ground. The Dow followed by the end of the morning, but the averages moved in a narrow range from there. Despite the range-bound trading, the market internals pointed to a pretty broad based move higher, with advancers ahead of declining stocks by almost 2 to 1. ECONOMIC EVENTS: In the U.S., no major domestic economic data was reported. COMPANY NEWS: AT&T (T) shares slid 36c, or 0.98%, to $36.38 after the company confirmed over the weekend that it has agreed to acquire DirecTV (DTV) for $95.00 per share, including $28.50 per share in cash and $66.50 per share in AT&T stock. After the announcement, analysts at Raymond James upgraded AT&T to Buy from Market Perform, noting that they do not expect another buyer to emerge for DirecTV. Meanwhile, DirecTV shares were downgraded to Equal Weight from Overweight at Evercore and to Hold from Buy at Wunderlich. Shares of DirecTV fell $1.53, or 1.77%, to $84.65 after the deal, which has been widely speculated about in the media in recent weeks, was confirmed... Also over the weekend, Pfizer (PFE) raised its bid for AstraZeneca (AZN), but the U.K. drugmaker again rejected this "final" takeover proposal. Shares of Pfizer rose 16c, or 0.55%, to $29.28 after the rejection, while shares of AstraZeneca trading in New York dropped $9.64, or 12.01%, to $70.64. MAJOR MOVERS: Among the notable gainers was InterMune (ITMN), which gained $4.61, or 13.44%, to $38.92 after reporting results from a study evaluating pirfenidone and having its shares upgraded to Outperform at Leerink. Also higher was NVIDIA (NVDA), which rose 58c, or 3.23%, to $18.54 after it was one of several semiconductor stock, along with Micron (MU), Texas Instruments (TXN), and Broadcom (BRCM), that were upgraded to Outperform from Sector Perform by RBC Capital in a note to investors earlier today. Among the noteworthy losers was LifeLock (LOCK), which fell $2.28, or 17.57%, to $10.70 after disclosing that the company is going to temporarily suspend its Wallet mobile application since it is not fully compliant with applicable payment card industry security standards. Also lower were shares of Campbell Soup (CPB), which dropped $1.06, or 2.35%, to $44.06 after the company reported mixed third quarter results and lowered its fiscal 2014 outlook. INDEXES: The Dow was up 20.55, or 0.12%, to 16,511.86, the Nasdaq was up 35.23, or 0.86%, to 4,125.81, and the S&P 500 was up 7.22, or 0.38%, to 1,885.08.
News For T;DTV;PFE;AZN;NVDA;MU;TXN;BRCM;CPB;LOCK;ITMN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 8, 2014
10:00 EDTMUOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:20 EDTBRCMQualcomm opportunity at Xiaomi almost rivals iPhone, says FBR Capital
Subscribe for More Information
08:09 EDTPFEPfizer presents LP2086 Phase 2 study data
Pfizer announced it will present the results of a Phase 2, randomized study to evaluate co-administration of the company’s investigational meningococcal group B vaccine, bivalent recombinant LP2086, or rLP2086, with a licensed quadrivalent human papillomavirus vaccine at IDWeek 2014. Data demonstrated immune responses to both vaccines were generated after concomitant administration of bivalent rLP2086 and HPV4. Prespecified noninferiority criteria were met for the bivalent rLP2086 antigens studied and three of the four antigens for HPV4. Primary immunogenicity endpoints, measured after the third dose, included geometric mean titers against HPV antigens in Groups 1 and 3 and human complement serum bactericidal assay GMTs against meningococcal group B disease test strains in Groups 1 and 2. Secondary immunogenicity endpoints included the rate of seroconversion to HPV antigens. Safety of bivalent rLP2086 was assessed after concomitant administration with HPV4 or saline. The prespecified noninferiority criteria were met for three of four HPV antigens and both meningococcal group B disease test strains. Seroconversion for all four HPV antigens was achieved by 99% or more of the subjects for the groups that received HPV4 concomitantly with bivalent rLP2086 or with saline. More local reactions occurred following administration of bivalent rLP2086 compared with saline but the incidence of these reactions did not increase with subsequent vaccine administration. The rates of local and systemic reactions were comparable when bivalent rLP2086 was given with HPV4 to bivalent rLP2086 given alone.
07:56 EDTBRCMBroadcom recently won large custom chip programs, says JPMorgan
Subscribe for More Information
07:43 EDTMUMicron initiated with a Neutral at Ladenburg
Subscribe for More Information
07:19 EDTPFECBI to hold a conference
Subscribe for More Information
07:18 EDTPFEInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
07:16 EDTCPBFood & Drug Law Institute to hold a conference
Food Advertising: Claims, Litigation & Strategies Conference is being held in New York on October 8.
October 7, 2014
10:43 EDTDTVOptions with decreasing implied volatility
Subscribe for More Information
10:17 EDTBRCMSamsung outlook miss weighs on suppliers
Subscribe for More Information
09:04 EDTDTVFox Sports Radio, DirecTV announce partnership to launch Rich Eisen Show
FOX Sports Radio (FOXA) and DIRECTV (DTV) announced a partnership to launch The Rich Eisen Show into national radio syndication. Eisen will debut as part of FOX Sports Radio’s national weekday lineup in the noon to 3 p.m. ET timeslot, beginning November 3. FOX Sports Radio/Premiere Networks will also provide exclusive radio ad sales representation for The Rich Eisen Show.
07:48 EDTAZNSalix reinstated with a Buy at Jefferies
Subscribe for More Information
07:48 EDTPFEU.S. Chamber of Commerce to hold a discussion
Subscribe for More Information
06:04 EDTTAT&T issues apology after customer info improperly accessed, Re/code reports
AT&T has issued an apology after an incident in which customer account information was improperly accessed by a worker, Re/code reports. A company spokesman says AT&T is contacting the limited number of affected customers and is also in contact with law enforcement regarding the issue. Reference Link
October 6, 2014
18:57 EDTNVDAU.S. ITC opens investigation into Samsung product infringement of NVIDIA patents
Subscribe for More Information
11:00 EDTDTVOptions with decreasing implied volatilit
Subscribe for More Information
08:55 EDTLOCKLifeLock should deliver beat and raise results, says Sterne Agee
Subscribe for More Information
08:27 EDTMUMicron lower in pre-market after Samsung plant plans confirmed
Subscribe for More Information
07:32 EDTAZNAstraZeneca confirms AHA, ACC updated guideline
AstraZeneca confirmed that the American Heart Association and American College of Cardiology have updated the guideline for the management of patients with non–ST-elevation acute coronary syndromes. The guideline supports differentiation among currently available P2Y12 inhibitors, including ticagrelor, clopidogrel, and prasugrel, for these patients. BRILINTA is now preferred over clopidogrel for the management of NSTE-ACS patients who undergo an early invasive or ischemia-guided strategy or those who receive a coronary stent. This is the first time the AHA and ACC have recommended one P2Y12 over another in the treatment of acute coronary syndrome. The approved Prescribing Information for BRILINTA includes information about the approved uses for BRILINTA. BRILINTA has two Boxed WARNINGS, one for bleeding risk and the other for aspirin dose and reduced BRILINTA effectiveness. The Boxed WARNING on BLEEDING RISK states, like other antiplatelet agents, BRILINTA can cause significant, sometimes fatal, bleeding.
07:09 EDTTAmerican Trucking Association to hold a conference
2014 ATA Management Conference is being held in San Diego on October 4-7.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use